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The inhibitory Fcg receptor modulates therapeutic antibody activity by setting a threshold for effector cell
activation and removing antibodies from the tumor cell surface. In this issue of Cancer Cell, Roghanian
and colleagues demonstrate that antibodies blocking inhibitory Fcg receptor function can enhance therapeu-
tic antibody activity to allow optimal tumor cell depletion.Tumor immunotherapy has been revolu-
tionized by the introduction of cyto-
toxic immunoglobulin G (IgG) antibodies.
While cellular Fcg receptors (FcgR),
recognizing the antibody fragment crys-
tallizable (Fc-fragment), are central medi-
ators of therapeutic antibody activity,
they also limit their cytotoxic effector
functions in vivo (Biburger et al., 2014;
Pincetic et al., 2014). The key molecule
in this process is the inhibitory FcgRIIB,
which is broadly expressed on cells of
the innate immune system and B cells.
Mice deficient in FcgRIIB show strongly
enhanced IgG-dependent effector func-
tions, demonstrating the potent inhibitory
activity of this receptor and its crucial
function as a checkpoint of IgG activity
(Smith and Clatworthy, 2010; Takai
et al., 1996). This may be of special
relevance for immunotherapy of lym-
phoma, where both the innate immune
effector cells responsible for eliminating
tumor cells as well as tumor cells them-
selves express the inhibitory FcgRIIB
(Figure 1). Indeed, previous studies
demonstrated that FcgRIIB expressed
on B cells or lymphoma cells can bind
to the Fc-fragment of the therapeutic
antibody, such as the CD20-specific
antibody rituximab, and trigger its inter-
nalization (Lim et al., 2011). Moreover,
ectopic FcgRIIB expression was also
identified on metastatic melanoma,
which argues for a broader relevance of
this immune escape mechanism (Cas-
sard et al., 2008). Thus, FcgRIIB not
only sets a threshold for innate immune
effector cell activation, but also limits
the availability of the therapeutic anti-body on tumor cells, making it a very
interesting target to enhance tumor
immunotherapy.
In this issue of Cancer Cell, Roghanian
et al. (2015) report on the generation of
new FcgRIIB-specific antibodies that
block the inhibitory function of FcgRIIB
and strongly enhance therapeutic anti-
body activity in vitro and in vivo. To
achieve this, Roghanian et al. (2015)
produced a series of FcgRIIB-specific
antibodies with the capacity to block
therapeutic antibody internalization by
tumor cells without inducing agonistic
inhibitory FcgRIIB signaling. One of these
antibodies (termed 6G11) showed a
superior specificity for human FcgRIIB,
did not trigger inhibitory signaling path-
ways, and enhanced the presence of
the therapeutic antibody on the tumor
cell surface (Roghanian et al., 2015). In
addition, the FcgRIIB-specific antibody
had a cytotoxic activity, which, on the
one hand, may be considered beneficial
to direct more cytotoxic activity toward
lymphoma cells, but, on the other hand,
may be a reason for concern due to
the widespread expression of FcgRIIB
in vivo. Thus, the effector cells required
for tumor cell depletion may also
become diminished, and a depletion of
neutrophils may render the patient
susceptible to infections. Moreover, a
cytotoxic attack on FcgRIIB-positive
endothelial cells may cause systemic
adverse events and destruction of the
vasculature (Biburger et al., 2011; Gane-
san et al., 2012). To address these
potential safety issues, the authors per-
formed a variety of ex vivo assays withCancer Celhuman peripheral blood cells and also
generated mouse strains expressing hu-
man FcgRIIB instead of its mouse coun-
terpart with or without the concomitant
expression of human CD20. In these clin-
ically relevant model systems, the 6G11
antibody did not deplete monocytes or
neutrophils, while more than half of the
B cells were deleted in an FcgR-depen-
dent manner.
To separate the cytotoxic function from
the ligand binding blocking function of the
FcgRIIB-specific antibody, the authors
generated an aglycosylated antibody
variant, which no longer binds to cellular
FcgRs, including FcgRIIB (Arnold et al.,
2007). Because this antibody variant was
as potent in boosting rituximab-mediated
B cell depletion in vivo as the fully
glycosylated antibody, this suggests that
the prevention of therapeutic antibody
internalization is indeed a major compo-
nent of its activity in vivo. Similar benefi-
cial effects on therapeutic antibody
activity were identified in tumor xenograft
model systems, allowing the study of
therapeutic antibody activity in clinically
relevant niches. Again, the combina-
tion of the FcgRIIB-blocking antibody
together with rituximab was superior to
treatment with rituximab alone. More
promisingly, chronic lymphocytic leuke-
mia isolates from treatment refractory
patients and mantle cell lymphoma cells
also showed an enhanced sensitivity
to rituximab-mediated depletion if the
FcgRIIB-blocking antibody was included
in the treatment. Of note, antibody ther-
apy was not accompanied by a major
secretion of pro-inflammatory cytokinesl 27, April 13, 2015 ª2015 Elsevier Inc. 427
Figure 1. Sensitizing Tumor Cells for Therapeutic Antibody Attack
In the absence of an FcgRIIB-blocking antibody, the therapeutic antibody (blue Y-shaped molecules) be-
comes internalized via FcgRIIB expressed on lymphoma cells, limiting the elimination of tumor cells via
antibody-dependent cellular cytotoxicity (ADCC) through innate immune effector cells. In contrast, the
addition of an FcgRIIB-blocking antibody (red Y-shapedmolecule) prevents therapeutic antibody internal-
ization, resulting in an optimal triggering of activating Fcg receptors (greenmolecules) on effector cells and
efficient tumor cell killing.
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mined in ex vivo human whole blood cul-
tures or in the transgenic mouse in vivo,428 Cancer Cell 27, April 13, 2015 ª2015 Elssuggesting that the antibody should not
cause major adverse effects and should
be safe to use.evier Inc.Altogether, the results presented in
this study identify the inhibitory FcgRIIB
as a safe and promising target for
adjuvanting or optimizing the activity
of cytotoxic antibodies currently used
in the clinic (Figure 1). While the
treatment of lymphoma patients may
be an obvious first choice for testing
this antibody in clinical trials, data
suggesting that other tumors may
also have an ectopic FcgRIIB expres-
sion argue for a broader applicability
of FcgRIIB-blocking antibodies to sensi-
tize tumor cells for immunotherapy of
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